Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced unaudited interim and annual consolidated financial results for the fourth quarter and year ended December 31, 2007. The unaudited financial results are subject to further review and potential adjustment as described under the section "Financial Information".

"Throughout 2007, we continued to build our business with the launch of new products, the receipt of regulatory approvals, and the establishment of new partnerships. We expect our new product pipeline and our portfolio of innovative currently marketed products to provide growth and opportunity in 2008 and beyond," said Dr. William Hunter, President and CEO of Angiotech.

"With our expanded sales and marketing team in place and many of our reorganization activities completed, we believe that we are well positioned to achieve our targets for sales growth and gross margin improvements in the coming year," said Tom Bailey, Chief Financial Officer of Angiotech. "We are confident that during 2008 we will begin to realize returns on the various investments we have made in our business over the last two years."

Fourth Quarter Financial Highlights

- Total revenue, as adjusted for non-recurring items, was

$70.7 million. Total revenue under generally accepted accounting

principles (GAAP) was $71.4 million.

- Net product sales, as adjusted, were $43.5 million, and were derived

primarily from sales of our various single use specialty medical

devices as well as from sales of medical device components to third

parties. Net produ
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Texas , April 20, 2015 ... surgeons for healing bone injuries. The orthobiologics market is ... opportunities for its stakeholders. The global orthobiologics market report ... forecast of revenue. The global orthobiologics market was valued ... reach $7,900.2 million by 2019, at a CAGR of ...
(Date:4/20/2015)... , April 20, 2015  Eli Lilly and ... data from several targeted cancer therapies, reflecting Lilly,s diverse ... (AACR) Annual Meeting 2015, held April 18-22 in ... Cancer Discoveries to Patients" is the theme of this ... Lilly,s commitment to broadening its portfolio of therapies that ...
(Date:4/20/2015)... TORONTO , April 20, 2015 /CNW/ - Portage ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... completed a collaborative research study that showed one of ... reduces inflammation in brain tissue through inhibition of NFkB ... The permeability of the blood brain ...
(Date:4/20/2015)... Global Stem Cells Group ... an annual gathering of aesthetic medicine experts and innovators. ... to introduce the company’s brand new training course that ... cell techniques. , The course is designed to ... aesthetic field, including facial aging caused by volume loss. ...
Breaking Biology Technology:Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3
... STOCKHOLM, January 21 Richter-Helm,BioLogics GmbH & Co. ... for the development and manufacturing of Athera,s novel ... binding of the,protein, Annexin A5, to endothelium. The ... of patients with Acute Coronary Syndrome and who,are ...
... Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today announced ... Company, LLP as its independent registered public accounting ... Company,s independent registered public accounting firm was approved ... appointment will result in cost savings for Immtech. ...
... 20 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; ... Deficiency Letter on January 13, 2009, indicating that it ... set forth in Nasdaq Marketplace Rule 4350(c)(1) (the "Rule"). ... a Director, which was announced publicly in a January ...
Cached Biology Technology:Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 2Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 3Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm 2Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1) 2
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... University biologists are part of an international research team ... remote Arctic lake provides compelling evidence of unprecedented environmental ... "Our findings show that the last several decades have ... Neal Michelutti, a research scientist at the Paleoecological Environmental ...
... An analysis of sediment cores indicates that biological and chemical ... the past 200,000 years and likely are the result of ... the University of Colorado at Boulder. While environmental ... shown to be tightly linked with natural causes of climate ...
... new ways to fight cancer and other diseases have ... circadian rhythm, says Liheng Shi, a researcher in Texas ... the roughly 24-hour cycle of physiological activities of humans, ... have had their research, currently focusing on the circadian ...
Cached Biology News:Queen's scientists on international team discover 'ecologically unique' changes in Arctic lake 2Arctic lake sediments show warming, unique ecological changes in recent decades 2Arctic lake sediments show warming, unique ecological changes in recent decades 3Texas A&M researchers find new mechanism for circadian rhythm 2
Mouse Nodal Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Biology Products: